Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
In 2006, the development of tesaglitazar was terminated on the basis of an estimated benefit/risk profile that was not expected to be superior to existing therapies
About the study The current study performed a randomized, double-blind, crossover trial at the Research Institute of the McGill University Health Centre in Montreal, Quebec, Canada, to investigate whether semaglutide improved glycemic control and other nonglycemic outcomes in patients with T1D and using AID
Moreover, the rising prevalence of obesity and type 2 diabetes (T2D) globally continues to significantly boost market demand, as GLP-1 agonists play an essential role in the treatment and management of these conditions
& Peltonen, M
US$ 22.53
US$ 21.28
US$ 29.26
US$ 21.64
